Detalhe da pesquisa
1.
Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer.
Nature
; 585(7825): 447-452, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32908313
2.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N Engl J Med
; 384(25): 2394-2405, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34081848
3.
Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply.
N Engl J Med
; 385(15): 1440, 2021 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34614338
4.
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.
Annu Rev Med
; 66: 455-70, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25341009
5.
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
Cancer Cell
; 13(2): 91-104, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18242510
6.
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Breast Cancer Res
; 16(3): 211, 2014 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-25093514
7.
AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody.
Allergy
; 74(10): 1985-1989, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30964550
8.
Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology.
J Allergy Clin Immunol
; 141(4): 1519-1523.e9, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29360527
9.
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
Mol Oncol
; 18(2): 369-385, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37866880
10.
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
J Clin Oncol
; 42(11): 1288-1300, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38301187
11.
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
Proc Natl Acad Sci U S A
; 107(22): 10208-13, 2010 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20479250
12.
Systemic Therapy for Hereditary Breast Cancers.
Hematol Oncol Clin North Am
; 37(1): 203-224, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36435611
13.
Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype.
Nat Commun
; 14(1): 7408, 2023 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37973922
14.
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
Oncogene
; 42(36): 2701-2709, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37491606
15.
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.
Cell Rep
; 42(5): 112484, 2023 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163373
16.
Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
Breast Cancer Res
; 14(6): 115, 2012 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-23146216
17.
Opinion: PARP inhibitors in cancer-what do we still need to know?
Open Biol
; 12(7): 220118, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35892198
18.
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis.
Clin Cancer Res
; 28(6): 1180-1191, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34921020
19.
The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.
Nat Cell Biol
; 24(1): 62-73, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35013556
20.
Biologic markers determine both the risk and the timing of recurrence in breast cancer.
Breast Cancer Res Treat
; 129(2): 607-16, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21597921